View Older Stories View More Recent Stories
-
Roth Trims PT on Enphase Energy (ENPH) to $1.50 Amid Restructuring, Equity Offering
-
Roka Bioscience, Inc. Completes Private Placement of Preferred Stock and Warrants
-
Roth Capital Starts Fate Therapeutics (FATE) at Buy
-
Roth Capital Assumes bluebird bio (BLUE) at Buy
-
Azure Power Global Limited Announces Launch of its Initial Public Offering
-
Streetinsider.com's Hot Lunchtime Reads 9/21: (LL) (RHT) (CUR) (TSLA)
-
Roth Capital Affirms Neuralstem (CUR) at 'Buy' Amid NSI-189 Enrollment Milestone
-
Capricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds
-
Klay Thompson, Kelly Slater, Rob Machado and 400 Individuals Supported Ryan Sheckler's Gala and 9th Annual Golf Tournament Sponsored by Oakley
-
Roth Capital Reaffirms Palatin Technologies (PTN) at 'Buy'; Focus Now on BMT Phase III Data
-
Roth Capital Reiterates Regeneron (REGN) at 'Buy' Following New Teva Pharma Ffasinumab Partnership
-
Pre-Open Stock Movers 09/16: (DEPO) (INTC) (GPRO) Higher; (NVAX) (DB) (ORCL) Lower (more...)
-
Capricor Therapeutics (CAPR) Prices 3M Common Stock Offering for Proceeds of ~$8.7M
-
Capricor Therapeutics Announces Pricing of Offerings of Common Stock
-
Roth Capital Starts Recro Pharma (REPH) at Buy
-
Roth Capital Affirms S&W Seed (SANW) at 'Buy' Following Q4 Results; Says Margin Improvement Remains Key
-
Callidus Software, Inc. (CALD) Prices 5.1M Common Stock Follow-on at $18.25/Share
-
CallidusCloud Announces Pricing of Follow-On Offering
-
After-Hours Stock Movers 09/15: (SCOR) (CAR) (P) Higher; (NVAX) (DB) (ORCL) Lower (more...)
-
Capricor Therapeutics (CAPR) Announces Common Stock Offering
-
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
-
Notable Analyst Rating Changes 9/15: (GPN) (AKRX) (EXTR) Upgraded; (VFC) (FGP) (ATRA) Downgraded
-
Pre-Open Stock Movers 09/15: (AERI) (ACRX) (NTWK) Higher; (SQNS) (PAH) (SRPT) Lower (more...)
-
Roth Capital Downgrades Apigee (APIC) to Neutral
-
Roth Capital Starts Sophiris Bio (SPHS) at Buy, $8 PT
-
RGS Energy Completes $2.8 Million Public Offering of Preferred Stock and Warrants
-
Roth Capital Positive on Heat Biologics (HTBX) as HS-110 Combo Phase 1b Enrollment Resumes
-
Callidus Software, Inc. (CALD) to Offer 4M Common Shares
-
CallidusCloud Announces Proposed Follow-On Offering
-
Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Initiation of LGD-6972 Phase 2 in T2D
-
B. Riley & Co. Promotes Head of Capital Markets Andy Moore to President
-
Roth Capital Downgrades Applied Genetic Technologies Corp. (AGTC) to Neutral
-
Roth Capital Affirms Bioblast Pharma (ORPN) at 'Buy'; Extension Study Data Shows Sustainable Improvements
-
Roth Remains Neutral on Peregrine Pharma (PPHM); Pipeline Advancing Well, but Catalysts Remain
-
RGS Energy (RGSE) Prices Unit Offering for Proceeds of ~$2.2M
-
RGS Energy Announces Pricing of Unit Offering
-
Roth Positive on BioLineRx (BLRX) Amid Latest BL-8040 Phase 2a Data in r/r AML
-
Buy Palatin Technologies (PTN) Ahead of Phase 3 BMT Data - Roth Capital
-
Medigus (MDGS) Prices 1.28M Registered Direct Offering at $1.15/ADS
-
Medigus Announces Pricing of $1.47 Million Registered Direct Offering
-
Streetinsider.com's Hot Lunchtime Reads 9/7: (AMD) (LGND) (EXPR) (GILD)
-
Roth Capital Upgrades Cogentix Medical (CGNT) to Buy
-
Roth Capital Bumps PT on Ligand Pharma (LGND) up to $151 Following Sparsentan Data; Affirms at 'Buy'
-
Inphi Corp. (IPHI) Announces Pricing of Increased Conv. Senior Notes Offering
-
Inphi Corporation Prices Offering of $250.0 Million of Convertible Senior Notes
-
Superior Drilling Products (SDPI) to Offer 5M Common Shares
-
Superior Drilling Products, Inc. Launches Common Stock Offering
-
Roth Capital Positive on Ligand Pharma (LGND) Ahead of Sept. Catalysts; Affirms at 'Buy'
-
Roth Capital Sees Relatively Flat Q3 for FuelCell (FCEL), But Says Co. Still has Robust Pipeline
-
Roth Capital Downgrades Interactive Intelligence (ININ) to Neutral
